Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion.
The introduction of activated recombinant factor VIIa (rFVIIa) has allowed elective surgery to be safely performed in haemophiliacs with inhibitors. The main problems associated with its use are the short half-life, necessitating frequent intravenous injections, and its very high cost. Here we describe, for the first time, the performance of total hip and knee replacements in a haemophiliac with inhibitors at the same operation. The amount of rFVIIa concentrate used (8.57 mg) was similar to that normally used for a single joint replacement. The use of continuous infusion allowed for easier administration and further contributed to the reduction in cost as it avoids the peak levels associated with bolus injections.
Tagariello
G
G
Servizio Trasfusionale, Centro Regionale per le Malattie del Sangue e Servizio di assistenza agli Emofilici, Castelfranco Veneto Hospital, Regione Veneto, Italy. tagariello@ulssasolo.ven.it
Bisson
R
R
Radossi
P
P
Petris
U
U
Zanardo
G
G
De Biasi
E
E
Risato
R
R
Polese
F
F
Davoli
P G
PG
D000328:Adult; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D019645:Arthroplasty, Replacement, Knee / Q000379:methods*; D005167:Factor VII / Q000008:administration & dosage*; D015942:Factor VIIa; D006395:Hemarthrosis / Q000601:surgery*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage*
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa